LEXX
Lexaria Bioscience Corp.
NASDAQ · Healthcare · Biotechnology · CA
$3.19
−3.04%Next report
Analyst consensus
- Next report date
- Oct 28, 2026
- EPS estimate
- -$0.90
- Revenue estimate
- $50.0K
Latest reported
- Last report date
- Jul 13, 2026
- EPS actual
- -$0.08
- EPS estimate
- -$0.06
- Revenue actual
- —
- Revenue estimate
- $54.4K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +17.9%
- Revenue beats (12Q)
- 4
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Jul 13, 2026 | -$0.06 | -$0.08 | Miss -33.33% | — |
| Apr 13, 2026 | -$0.10 | -$0.06 | Beat 40.00% | $20.0K |
| Jan 13, 2026 | -$0.13 | -$0.07 | Beat 46.15% | $50.0K |
| Nov 26, 2025 | -$0.16 | -$0.13 | Beat 18.75% | $174.0K |
| Jul 14, 2025 | -$0.15 | -$0.21 | Miss -40.00% | $174.0K |
| Apr 14, 2025 | -$0.16 | -$0.15 | Beat 6.25% | $174.0K |
| Jan 10, 2025 | -$0.12 | -$0.16 | Miss -33.33% | $183.9K |
| Nov 26, 2024 | -$0.11 | -$0.15 | Miss -36.36% | $84.0K |
| Jul 12, 2024 | -$0.10 | -$0.13 | Miss -30.00% | $84.0K |
| Apr 9, 2024 | -$0.10 | -$0.06 | Beat 40.00% | $145.0K |
| Jan 12, 2024 | -$0.11 | -$0.13 | Miss -18.18% | $151.3K |
| Nov 21, 2023 | -$0.17 | -$0.12 | Beat 29.41% | -$3.4K |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Oct 28, 2026